The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.
Source: FDA drug updates
This item was collected automatically from an official industry feed. Follow the source link for the complete announcement and primary documentation.